NanJing Pharmaceutical Co Ltd
SSE:600713
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
NanJing Pharmaceutical Co Ltd
NanJing Pharmaceutical Co Ltd
Total Current Liabilities
NanJing Pharmaceutical Co Ltd
Total Current Liabilities Peer Comparison
1099
601607
600998
000963
Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
NanJing Pharmaceutical Co Ltd
SSE:600713
|
Total Current Liabilities
¥18.6B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
8%
|
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Total Current Liabilities
¥281.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
15%
|
|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Total Current Liabilities
¥122.4B
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
16%
|
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Total Current Liabilities
¥60.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
18%
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Total Current Liabilities
¥13.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
19%
|
|
|
Huadong Medicine Co Ltd
SZSE:000963
|
Total Current Liabilities
¥10.8B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
See Also
What is NanJing Pharmaceutical Co Ltd's Total Current Liabilities?
Total Current Liabilities
18.6B
CNY
Based on the financial report for Mar 31, 2024, NanJing Pharmaceutical Co Ltd's Total Current Liabilities amounts to 18.6B CNY.
What is NanJing Pharmaceutical Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
8%
Over the last year, the Total Current Liabilities growth was -20%.
You don't have any saved screeners yet
